The Food and Drug Administration June 16 released violation letters that it sent to Sepracor, Cumberland Pharmaceuticals, Eisai, and Auxilium Pharmaceuticals over promotional materials for four prescription drugs.
The agency’s Division of Drug Marketing, Advertising, and Communications (DDMAC) sent so-called untitled letters to Sepracor regarding a television advertisement for Lunesta (eszopiclone), to Cumberland regarding a sales aid for Acetadote (acetylcysteine), to Eisai regarding a consumer-directed video for Gliadel wafer (polifeprosan 20 with carmustine implant), and to Auxilium regarding a patient brochure for Xiaflex (collagenase clostridium histolyticum).
An untitled letter cites violations that do not meet the threshold of regulatory significance ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.